Medtronic, on March 10, 2026, announced a definitive agreement to acquire Scientia Vascular for $550 million, with potential additional milestone payments. Scientia, which is based in Salt Lake City, Utah, has around 310 employees and specializes in guidewires as well as catheters when it comes to neurovascular procedures.
The deal is most likely to close in the first half of FY2027, pending certain regulatory approvals.
The fact is that this acquisition strengthens the Medtronic neurovascular portfolio, combining its therapeutic technologies with access products of Scientia.
The innovations of Scientia enhance navigability by way of a complex cerebral vasculature, helping with much faster and more reliable access at the time of stroke interventions. This integration supports the physicians across the full procedural workflow for both hemorrhagic and ischemic strokes.
It is well to be noted that stroke is the third leading cause of death and the leading cause of disability across the world.
The microwire and microcatheter technology by Scientia simplifies the procedures, thereby making them much safer and faster as well as more efficient. Physicians go on to stress that improved access tools can significantly elevate the outcomes in patients.
Medtronic executives highlight the acquisition as a way to accelerate innovation within Medtronic neurovascular portfolio and expand into new disease states. According to senior vice president and president of Medtronic’s Neurovascular business, which is part of the Neuroscience Portfolio at Medtronic, Linnea Burman, “Medtronic is thrilled to acquire Scientia to accelerate meaningful innovation in neurovascular care. This acquisition positions Medtronic with a full suite of products. It builds a strong foundation for Medtronic and supports procedures across both hemorrhagic and acute ischemic stroke. Medtronic’s best-in-class therapies, combined with Scientia’s leading access portfolio, will be incredibly powerful. With 12 million people globally suffering from stroke each year, we look forward to contributing to better patient outcomes around the world.”
Scientia’s CEO eyes the deal as an opportunity to scale globally and broaden effect. Says CEO of Scientia, Rick Randall, “As a company committed to improving patients’ lives, we are humbled and excited for what’s ahead. Scientia has developed critical technology that has been embraced by physicians. This deal allows us to take our engineering into disease states globally and positions Medtronic with a comprehensive portfolio and complete guidewire line. With the size and scale of Medtronic, the opportunity to treat more patients and drive more impact is truly exciting.”
According to the director of the Cerebrovascular Center at Stony Brook Medicine, David Fiorella, “Microwires and microcatheters are required for all neurointerventional cases. Correspondingly, better microwires and microcatheters make every single case technically easier, faster, and ultimately safer for patients. This revolutionary microwire technology has enabled and will continue to enable access and simplify the neurovascular procedures we do.”
The transaction is anticipated to be minimally dilutive to FY27 EPS and accretive thereafter.
